Skip to content
Sign inOpen the app
Artwork for The Readout Loud
The Readout Loud · April 23 · 37 min

398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts

How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugmakers working with a telehealth company called Prescribery? We discuss all that and more on this week's episode of "The Readout LOUD," STAT's weekly biotech podcast. Venture capitalist Bryan Roberts joins us to discuss his firm’s investment in Kelonia Therapeutics, the CAR-T biotech that Eli Lilly just said it would buy for $3.25 billion. We also bring on our colleague Katie Palmer to talk through her story about pharma companies using bargain-basement telehealth providers to drive drug prescriptions and sales.

0:00-37:50
Play in podnod

transcript

No transcript — this publisher did not publish one.

show notes

How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugmakers working with a telehealth company called Prescribery?


We discuss all that and more on this week's episode of "The Readout LOUD," STAT's weekly biotech podcast. Venture capitalist Bryan Roberts joins us to discuss his firm’s investment in Kelonia Therapeutics, the CAR-T biotech that Eli Lilly just said it would buy for $3.25 billion.


We also bring on our colleague Katie Palmer to talk through her story about pharma companies using bargain-basement telehealth providers to drive drug prescriptions and sales.

more episodes

All episodes